The US Food and Drug Administration (FDA) has cleared Edwards Lifesciences’ Sapien transcatheter aortic heart valve, designed to treat inoperable patients with severe symptomatic aortic stenosis.
The Sapien valve, designed for transfemoral delivery in patients with severe symptomatic native aortic valve stenosis, enables transcatheter aortic valve replacement, preventing the need for cardiopulmonary bypass.
The approval follows the randomised controlled pivotal Partner trial, which evaluated the safety and effectiveness of the Sapien transcatheter valve.
The Partner trial also showed that patients receiving the Sapien valve experienced better quality of life as compared to patients in the control group.
How well do you really know your competitors?
Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.
Your download email will arrive shortly
Not ready to buy yet? Download a free sample
We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below formBy GlobalData